J.Jpn. Surg. Soc.
ISSN 1880-1129

[Abstract] [Full Text PDF] （in Japanese / 2566KB） [Members Only And Two Factor Auth.]

J.Jpn. Surg. Soc.. 85(9): 1151-1156, 1984

Report on the annual meeting

ARTERIAL ADMINISTRATION THERAPY WITH SMANCS AND THE OTHER ANTITUMOR AGENTS DISSOLVED IN LIPIODOL FOR VARIOUS MALIGNANT SOLID TUMORS

1) First Dept of Surgery, Kumamoto University Medical school, Kumamoto, Japan
2) Dept of Microbiology, Kumamoto University Medical School, Kumamoto, Japan
3) Kanebo Hospital, Kobe, Japan

Toshimitsu Konno1), Ken Iwai1), Shojiro Maki1), Seiki Tashiro1), Yoshimasa Miyauchi1), Hiroshi Maeda2), Ikuzo Yokoyama3)

Selective deposition of lipiodol in primary and metastatic liver cancer, lung cancer, gallbladder cancer, pancreatic cancer and renal cancer was elucidated by plain X-ray film and CT. Selective delivery of anticancer agent, SMANCS was also proved by measurement of its biological activities of removed specimen. Because of these selective delivery of anticancer agent and embolization of neovasculature in the tumor, highly effective chemotherapy of unresectable cancer was established. Drug was given via celiac, the hepatic, bronchial or renal artery mostly 1-5 mg in 1-5 ml of lipiodol once every 3-8 weeks. Antitumor effects of this therapy for hepatocellular carcinoma was confirmed based on decrease in AFP levels (92% of the cases), reduction in tumor size (90% of the cases) and histology. In 76 percent of the patients with the other malignant solid tumors reduction in tumor size was recognized. Decrease in CEA level occurred in 88 percent of the cases with metastaic liver cancer and lung cancer. Major side effect was transient fever in about 50% of cases. Mitomycin C and aclarubicin dissolved in lipiodol showed remarkable antitumor effects for experimental liver cancer.

<< To previous pageTo next page >>

To read the PDF file you will need Adobe Reader installed on your computer.